MOTS-c is a 16-amino-acid peptide with an unusual origin: rather than being encoded by the cell's main DNA, it is encoded within a short region of the mitochondrial genome (the 12S rRNA gene).1
Peptides like this are called "mitochondrial-derived peptides," and they appear to act as signals that help regulate metabolism and cellular energy.12
Its sequence is Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg.
MOTS-c is naturally present in the body in tiny amounts, but the synthetic version sold and studied is a laboratory-made compound. It is not an FDA-approved drug.
In plain English: MOTS-c is a tiny signal your body's energy factories (mitochondria) make - especially when you exercise.
What the research shows - and what it doesn't
Laboratory and animal research links MOTS-c to metabolic regulation - improving insulin sensitivity and influencing weight and bone metabolism in study models.12
There is also some human observational data: MOTS-c levels rise with exercise, and lower levels have been associated with obesity and higher fasting insulin in some studies.1
What the record does not include is large, well-controlled human trials showing that giving MOTS-c is safe and effective for obesity, osteoporosis, or anything else. Reviewers also note practical hurdles - poor stability and bioavailability - that have slowed its development as a therapy.2
Why MOTS-c is called 'exercise in a molecule'
MOTS-c is fascinating because it's a message from the mitochondria themselves - a signal your cells release when you exercise. In studies it improves insulin sensitivity, resists weight gain, and supports bone and muscle, and human data shows it rises with training and runs low in metabolic disease.12
That "exercise in a molecule" framing is irresistible - and early research
partly
supports it - but the large human trials that would settle it are still missing.2
How to read peptide research. Animal-study and cell-study findings describe what happened in a controlled experiment. They are a starting point for investigation, not evidence that a compound works - or is safe - in humans. Peppies does not claim any peptide treats, cures, or prevents any condition.
In plain English: In studies it helped with blood sugar, weight, and bones, and it rises when people work out. Still, big human trials haven't proven it as a treatment.
Is MOTS-c legal in 2026?
Here is the direct answer as of July 2026:
It is not an FDA-approved drug. There is no approved MOTS-c product for any medical use.
It cannot be lawfully sold as a dietary supplement. The FDA treats unapproved injectable peptides marketed for human use as outside the lawful supplement framework.4
It currently has no cleared compounding pathway. MOTS-c was placed in "Category 2" of the FDA's interim list of bulk drug substances for pharmacy compounding under section 503A - the category for substances that raise significant safety concerns - and although the FDA removed it (with eleven other peptides) from Category 2 in April 2026 and referred it to the advisory committee, removal did not add it to the approved ("Category
1") list.56
In plain terms, MOTS-c sits in a regulatory gap: removed from the explicitly-restricted bucket, but not placed into an approved one.4
This section is educational and is not legal advice. Rules can vary and change; consult a qualified professional for your situation.
In plain English: It's not approved to sell as a medicine or supplement, and can't be legally made-to-order yet.
The regulatory timeline
Sep 2023
FDA adds this and other peptides to Category 2 of the interim 503A bulks list, citing safety concerns such as limited human data.3
Apr 2026
FDA removes 12 peptides - including this one - from Category 2 and sets an advisory committee review.56
Jul 23, 2026 (Day 1)
The Pharmacy Compounding Advisory Committee meets to review seven peptides. The FDA-evaluated use here is obesity and osteoporosis.3
After the meeting
The committee's vote is advisory only. FDA then decides whether to begin formal rulemaking to add (or not add) this peptide to the 503A list. In its briefing materials, FDA staff proposed not adding the peptides under review.37
Where the public comes in
The July 23-24 advisory meeting has its own public docket (FDA-2025-N-6895), but that docket closes July 22, 2026, and the committee's vote is only a recommendation. The decision that actually determines access comes later, if and when the FDA opens a formal rulemaking. That is the public comment window that carries legal weight - and it is the moment Peppies is tracking.
Want to know the moment you can comment?
Join the list and we'll send a clear, step-by-step heads-up when the official public comment window opens - so your voice counts when it matters.
MOTS-c is not an FDA-approved drug and has no cleared compounding pathway. It was in Category 2 of the interim 503A list, then removed in April 2026 and referred to the July 2026 advisory committee. Removal did not place it on the approved list.356
What was MOTS-c evaluated for at the July 2026 meeting?
The FDA-evaluated uses listed for MOTS-c are obesity and osteoporosis.3
Does exercise really raise MOTS-c?
Some human studies report that MOTS-c levels increase with exercise, and that lower levels correlate with obesity and higher fasting insulin. These are associations from observational research, not proof that supplementing MOTS-c produces a health benefit.1
Where to learn more
Want to dig into the primary science yourself? These are neutral, authoritative starting points - no sales pitch, just the record:
We link only to independent, authoritative sources - U.S. and international (NIH, FDA, Europe PMC/EMBL-EBI, and the EU/U.S. trial registries) - never to sellers.
U.S. Food and Drug Administration. "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee." Agenda, evaluated uses, briefing materials, and docket FDA-2025-N-6895. fda.gov - PCAC July 2026 meetingwww.fda.gov
U.S. Food and Drug Administration - consumer information on unapproved peptide products and dietary-ingredient status. fda.gov - compounding Q&Awww.fda.gov
Federal Register. "Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments - Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List." April 16, 2026. federalregister.govwww.federalregister.gov
Hyman, Phelps & McNamara. "FDA's Pep(tide) Rally: What Compounders and Industry Need to Know." FDA Law Blog, April 2026 (12 peptides removed from Category 2). thefdalawblog.comwww.thefdalawblog.com
